About Contact Us Careers

Avascular Necrosis Market Size and Forecast, by End user (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); Type; Treatment; Diagnosis - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 7016
  • Published Date: Dec 02, 2025
  • Report Format: PDF, PPT

Avascular Necrosis Market Outlook:

Avascular Necrosis Market size was valued at USD 590.93 million in 2025 and is expected to reach USD 1.05 billion by 2035, expanding at around 5.9% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of avascular necrosis is evaluated at USD 622.31 million.

Avascular Necrosis Market size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

The avascular necrosis market is growing substantially due to increased obesity levels, the application of corticosteroids, and over-imbibing alcohol. For instance, according to the World Obesity Atlas 2022, published by the World Obesity Federation, it is estimated that by 2030, 1 billion people worldwide will be living with obesity, which includes 1 in 5 women and 1 in 7 men. The estimates across the world state that around 2.3 billion children and adults live with overweight and obesity. With these trends ongoing, up to 1 billion adults, or 12% of the population would live with obesity by 2025.

Furthermore, the aging population aggravates this trend, as age-related degenerative changes increase susceptibility to joint disorders including AVN. For instance, according to the World Population Prospects 2022, the percentage of people in the global population aged 65 years and above is predicted to increase from 10% in 2022 to 16% in 2050. It is estimated that by 2050, individuals aged 65 years or older globally will be equal to twice that of children who are below age 5, and almost at par with that of children aged below 12 years. Therefore, there is a need for a management approach that encompasses both prevention and treatment of avascular necrosis.

Key Avascular Necrosis Market Insights Summary:

  • Regional Insights:

    • By 2035, North America is anticipated to secure over 39.7% share of the avascular necrosis market owing to its strong adoption of innovative treatment methods and well-established pharmaceutical presence.
    • Asia Pacific is set to experience lucrative growth throughout 2026–2035 due to the escalating demand for minimally invasive care and continuous enhancements in regional healthcare infrastructure.

  • Segment Insights:

    • By 2035, the hospitals with pharmacies segment is projected to command over 59.6% share of the avascular necrosis market, fueled by specialized pharma care and the shift toward integrated hospital-based patient management.
    • The CT scan subsegment is expected to dominate by 2035, supported by its advanced imaging accuracy that enables timely and precise diagnosis.

  • Key Growth Trends:

    • Research funding and clinical trials
    • Emergence of regenerative medicines

  • Major Challenges:

    • Comorbidity issues
    • High treatment costs

  • Key Players: Novartis AG, AbbVie Inc., Merck & Co. Inc., Pfizer Inc., Mylan N.V, Zimmer Biomet, Merck & Co. Inc, Enzo Biochem Inc, Atnahs, Bone Therapeutics SA, Vericel Corporation.

Global Avascular Necrosis Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 590.93 million
    • 2026 Market Size: USD 622.31 million
    • Projected Market Size: USD 1.05 billion by 2035
    • Growth Forecasts: 5.9%

  • Key Regional Dynamics:

    • Largest Region: North America (39.7% Share by 2035)
    • Fastest Growing Region: Asia Pacific
    • Dominating Countries: United States, Germany, Japan, United Kingdom, China
    • Emerging Countries: India, Brazil, South Korea, Mexico, Australia

    • Last updated on : 2 December, 2025

Growth Drivers

  • Research funding and clinical trials: The avascular necrosis market is stimulated by research funding and clinical trials as they allow for the investigation of new therapeutic strategies and deepen our understanding of the disease's pathophysiology. Consequently, both the public and private sectors are investing heavily. Such efforts include regenerative medicine approaches and advanced surgical techniques. For instance, in September 2023, CIRM invested USD 44 million to enhance research and manufacturing in regenerative medicine in California. In addition, Novoglia, Inc. received a USD 1.4 million award for the development of a cell therapy for ALSP.
  • It not only works to improve the results for the patients but also encourages collaboration between researchers, clinicians, and pharmaceutical companies in accelerating the identification of suitable treatments. For instance, in November 2024, Exeter research aims to revolutionize hip surgery with robotic assistance. The HIPSTER study is focused on improving the experience of people undergoing total hip replacement surgery to treat severe arthritis. Successful trials will eventually gain further funding and propel avascular necrosis market expansion through the translation of research findings into clinically applicable solutions to manage AVN.
  • Emergence of regenerative medicines: The catalyst growth driver for the avascular necrosis market is the effects of multiple therapeutic agents as they ensure overall efficacy in the treatment of cancer. The incorporation of avascular necrosis with chemotherapy or targeted therapies allows clinicians to achieve a better patient outcome, which also encompasses higher response rates and extended survival. For instance, in March 2024, by creating a 3D model of the lesion developed at Yale, healthcare professionals can target avascular necrosis with minimally invasive techniques to protect the integrity and strength of the bone.
  • New approaches such as stem cell therapy, PRP injections, and tissue engineering are being found to be very promising in helping the healing process and regeneration of vascular supply to the affected regions. For instance, in July 2024, PacBio entered an agreement with Novogene to further move forward in the field of genomics together with applications impacting tissue engineering-related fields such as rare diseases and oncology. These approaches eliminate the shortcomings of traditional treatment modalities and open up the scope for better outcomes and reduced long-term disability.

 Challenges

  • Comorbidity issues: The biggest challenge to the avascular necrosis market is comorbidity issues because a patient will mostly have concurrent multiple health conditions which complicate both diagnosis, treatment, and total management. Some common comorbidities, including diabetes, cardiovascular diseases, and obesity, accelerate the progression of AVN and prevent therapeutic interventions from being maximally effective. Patients with such conditions pose a need for more comprehensive, multidisciplinary care that burdens healthcare resources and complicates decision-making. This also complicates the management of AVN which targets each cause of the AVN plus its comorbidity.
  • High treatment costs: One of the major challenges facing the avascular necrosis market is the high cost associated with its treatment, for both the patient and healthcare systems, as managing this condition can be quite pricey. Advanced treatments usually involve surgical intervention, in the form of joint replacement and new regenerative therapies, which are costly and often not covered by medical insurance in many places. Thus, these economic and high treatment costs reduce the accessibility of treatment for many patients, especially the deprived classes or underdeveloped countries with minimal medical care. Such expenses in care management and rehabilitation increase the cost of the disorder in terms of finance to the sufferers.

Avascular Necrosis Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Year

2026-2035

CAGR

5.9%

Base Year Market Size (2025)

USD 590.93 million

Forecast Year Market Size (2035)

USD 1.05 billion

Regional Scope

  • North America (U.S. and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, South Korea, Malaysia, Australia, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Avascular Necrosis Market Segmentation:

End user Segment Analysis

Hospitals with pharmacies segment is set to hold avascular necrosis market share of over 59.6% by the end of 2035. Owing to its specialized pharma care towards specifically tailored drug use regimens, it is necessary for treating patients having avascular necrosis. In addition, because hospitals are becoming increasingly focused on adopting integrated care models emphasizing comprehensive patient management, a corresponding increase in demand is expected to be registered for specialized services offered by hospital pharmacies. For instance, in October 2023, based on the information contained in the Central Register of Pharmacies on 9th September 2022, it was reported that in the Polish health establishments, there exist 565 hospital pharmacies and 1035 pharmacy departments in the hospital.

Diagnosis Segment Analysis

The CT scan subsegment is anticipated to dominate the avascular necrosis market by 2035 attributable primarily to the superior imaging capabilities that allow for an accurate and timely diagnosis. CT scans provide cross-sectional images of bone structures with much more detail than conventional X-rays, which can make early-stage AVN changes more visible. For instance, in February 2024, Royal Philips launched its new CT 5300 system with advanced AI capabilities, intended to be used for diagnosis, interventional procedures, and screening. The flexible X-ray CT system increases diagnostic confidence, streamlines workflow efficiency, and maximizes system up-time, thus improving patient outcomes and department productivity.

Our in-depth analysis of the global market includes the following segments:

Type

  • Trauma related avascular necrosis
  • Non-trauma-related avascular necrosis

Treatment
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Cholesterol Lowing Drugs
  • Osteoporosis Drugs
  • Blood Thinners
  • Others

Diagnosis
  • Imaging
  • Biopsy
  • CT scan
  • PET
  • X-ray

End user

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Avascular Necrosis Market - Regional Analysis

North America Market Insights

North America avascular necrosis market is predicted to capture revenue share of over 39.7% by 2035. The region emphasizes the applicability of avascular necrosis in people and is more willing to embrace innovative treatment methods. This market will probably grow with public concern for avascular necrosis medical conditions and diagnostics with furthering the development owing to the presence of strong and well-established pharmaceutical giants.

The U.S. avascular necrosis market is unfolding remarkable growth opportunities attributable to the growing instances of osteoporosis amongst the population, which is driving demand for therapeutic drugs and effective diagnostics treatments. For instance, in May 2024, according to the FDA, it was found that osteoporosis is one of the common causes of fractures in postmenopausal women and in older me in the U.S. Of the estimated 10 million Americans with osteoporosis, more than 8 million (80%) are women. In the United States, osteoporosis affects one in four women aged 65 or older, but younger women can also get osteoporosis.

The Avascular necrosis market in Canada is witnessing significant growth due to a robust regulatory framework and a conducive environment through legislations that allow newly developed drugs to flourish. For instance, in May 2024, Health Canada provided marketing authorizations to Jubbonti. It is the first and only Health Canada-approved denosumab biosimilar for osteoporosis and increasing bone mass. It was made available in the local markets in the coming months.

Asia Pacific Market Insights

The avascular necrosis market in Asia Pacific is gaining traction and is expected to witness lucrative growth during the forecast timeline i.e. 2026-2035. This growth is driven further by the rapidly rising need for minimally invasive care and reliance on surgery to handle osteonecrosis. Regional government's improvement in healthcare infrastructures and up-gradation is driving the market ahead through the increase of options in the number of available hospitals.

The avascular necrosis market in India is expecting substantial growth owing to the innovative researches in the field of bone-related study which focus on improving the medical conditions of patients suffering from osteonecrosis. For instance, in February 2021, Novosteo Inc. announced that it had closed its series A financing to an amount totaling USD 5.5 million to advance the development of the very first targeted bone anabolic agent NOV004.

The avascular necrosis market in China is gaining traction due to effortless approvals from government agencies which has enabled patients to access new and innovative treatments. For instance, in September 2024, the Ministry of Commerce issued a circular on its official website announcing the expansion of pilot programs for opening up the medical sector. This circular lift bans on foreign-invested enterprises (FIEs) engaging in cell and gene therapy (CGT) in selected free trade zones (FTZs) and permits wholly foreign-owned hospitals in selected cities.

Avascular Necrosis Market share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Avascular Necrosis Market Players:

    The companies participating in the avascular necrosis market are playing an important role in developing new treatment options and improving patient care through innovative research, development, and commercialization of therapeutic products. For instance, in March 2024, HVD Life Science collaborated with Poietis to distribute the NGB-R platform from Poietis in Australia and Germany. This collaboration brings cutting-edge bioprinting technology to the forefront of R&D in tissue engineering and regenerative medicine.

    Here's the list of some key players:

    • Novartis AG
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • AbbVie Inc.
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Mylan N.V
    • Zimmer Biomet
    • Merck & Co. Inc
    • Enzo Biochem Inc
    • Atnahs
    • Bone Therapeutics SA
    • Vericel Corporation

Recent Developments

  • In June 2024, Cryoport, Inc. and Minaris Regenerative Medicine Co., Ltd., announced a strategic partnership aimed at offering end-to-end logistics and manufacturing services for regenerative medicines for cell and gene therapy development.
  • In January 2023, BioMed X and AbbVie expanded their research collaboration.  This research collaboration aimed at looking at immunology and tissue engineering.
  • Report ID: 7016
  • Published Date: Dec 02, 2025
  • Report Format: PDF, PPT
  • Explore a preview of key market trends and insights
  • Review sample data tables and segment breakdowns
  • Experience the quality of our visual data representations
  • Evaluate our report structure and research methodology
  • Get a glimpse of competitive landscape analysis
  • Understand how regional forecasts are presented
  • Assess the depth of company profiling and benchmarking
  • Preview how actionable insights can support your strategy

Explore real data and analysis

Download Free Sample Report

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of avascular necrosis is evaluated at USD 622.31 million.

The global avascular necrosis market size exceeded USD 590.93 million in 2025 and is set to expand at a CAGR of over 5.9%, surpassing USD 1.05 billion revenue by 2035.

By 2035, North America is anticipated to secure over 39.7% share of the avascular necrosis market owing to its strong adoption of innovative treatment methods and well-established pharmaceutical presence.

Key players in the market include Novartis AG, AbbVie Inc., Merck & Co. Inc., Pfizer Inc., Mylan N.V, Zimmer Biomet, Merck & Co. Inc, Enzo Biochem Inc, Atnahs, Bone Therapeutics SA, Vericel Corporation.

Avascular Necrosis Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos